Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing
Rule or Standard; Transfer of Listing
On April 3, 2023, Nemaura Medical Inc. (the “Company”)
received a written notice (the “MVLS Notice”) from the Nasdaq Listing Qualification Department (the “Nasdaq Staff”)
indicating that the Company is not in compliance with the $35 million minimum market value of listed securities requirement set forth
in Nasdaq Listing Rule 5550(b)(2) for continued listing on the Nasdaq Capital Market. The notification of noncompliance has no immediate
effect on the listing or trading of the Company’s common stock on the Nasdaq Capital Market under the symbol “NMRD,”
and the Company is currently monitoring the market value of its listed securities and evaluating its alternatives, if appropriate, to
resolve the deficiency and regain compliance with this rule.
The Nasdaq Listing Rules (the “Rules”)
require listed securities to maintain a minimum market value of listed securities (“MVLS”) of $35 million and, based on the
Nasdaq Staff’s review of the Company’s MVLS for the last 30 consecutive business days, the Company no longer meets this requirement.
However, the Rules also provide the Company a compliance period of 180 calendar days, or until October 2, 2023, in which to regain compliance.
If at any time during this compliance period the Company’s MVLS closes at $35 million or more for a minimum of 10 consecutive business
days, the Nasdaq Staff will provide the Company written confirmation of compliance and this matter will be closed. There
can be no assurance that the Company will be able to regain compliance with the MVLS requirement, even if it maintains compliance with
the other listing requirements.
On April 7, 2023, the Company received written notice
(the “Bid Price Notice”) from the Nasdaq Staff indicating that the Company is not in compliance with the $1.00 Minimum Bid
Price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market. The notification of
noncompliance has no immediate effect on the listing or trading of the Company’s common stock on the Nasdaq Capital Market under
the symbol “NMRD,” and the Company is currently monitoring the closing bid price of its common stock and evaluating its alternatives,
if appropriate, to resolve the deficiency and regain compliance with this rule.
The Nasdaq Listing Rules require listed securities
to maintain a minimum bid price of $1.00 per share and, based upon the closing bid price for the last 30 consecutive business days, the
Company no longer meets this requirement. The Bid Price Notice indicated that the Company will be provided 180 calendar days, or until
October 3, 2023, in which to regain compliance. If at any time during this period the bid price of the Company’s common stock closes
at or above $1.00 per share for a minimum of 10 consecutive business days, the Nasdaq Staff will provide the Company with a written confirmation
of compliance and the matter will be closed.
Alternatively, if the Company fails to regain compliance
with Rule 5550(a)(2) prior to the expiration of the 180 calendar day period, but meets the continued listing requirement for market value
of publicly held shares and all of the other applicable standards for initial listing on the Nasdaq Capital Market, with the exception
of the minimum bid price, and provides written notice of its intention to cure the deficiency during the second compliance period by effecting
a reverse stock split, if necessary, then the Company may be granted an additional 180 calendar days to regain compliance with Rule 5550(a)(2).
There can be no assurance that the Company will be
able to regain compliance with the Bid Price requirement, even if it maintains compliance with the other listing requirements. The Company
is considering actions that it may take in response to the Bid Price Notice in order to regain compliance with the continued listing requirements,
but no decisions regarding a response have been made at this time.